²é¿´: 1090  |  »Ø¸´: 3
¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß ºÏ·ÊëÄ¿âÉúÎï µÄ 5 ¸ö½ð±Ò £¬»ØÌû¾ÍÁ¢¼´»ñµÃ 1 ¸ö½ð±Ò£¬Ã¿ÈËÓÐ 1 ´Î»ú»á

ºÏ·ÊëÄ¿âÉúÎï

гæ (ÖøÃûдÊÖ)


[½»Á÷] ÐÞÊÎÐÔëĺËËáµÄϸ°ûתÔË

Áõ´º¶¬, Íõ½¨»ª, Ôø·¼Chin J Biotech, 2016, 32(3): 292-305
ÕªÒª

ëĺËËáÊÇÈ˹¤ºÏ³ÉµÄ¹ÑºËÜÕËáÀàËÆÎÒÔN-(2-°±ÒÒ»ù) ¸Ê°±Ëá½á¹¹µ¥ÔªÌæ´úDNA·Ö×ÓÖеÄÎìÌÇ-Á×Ëá½á¹¹¡£ÓëÌìÈ»ºËËáÏà±È£¬ëĺËËá¿ÉÒÔ¸ü¸ßЧµØÓëDNA»òRNAÌØÒìÐÔÔÓ½»£¬ÔÚ·Ö×ÓÉúÎïѧºÍ»ùÒòÒ©ÎïÁìÓò¾ßÓÐÁ¼ºÃµÄÓ¦ÓÃǰ¾°¡£µ«ÊÇ£¬ëĺËËá¹Ç¼Ü³ÊµçÖÐÐÔ£¬ÄÑÒÔ¸ßЧ´©¹ýϸ°ûĤ£¬Õâ³ÉΪ¹¤³ÌÓ¦ÓõÄ×î´óÕϰ­¡£ÎªÁ˸ÄÉÆëĺËËáµÄϸ°ûתÔËÐÔÄÜ£¬¶ÔëĺËËá½øÐл¯Ñ§ÐÞÊÎÊǽüÄêÀ´µÄÑо¿Èȵ㡣½áºÏ½üÊ®ÄêÀ´ÎÄÏ×±¨µÀºÍ±¾ÊµÑéÊҵŤ×÷£¬¶ÔëĺËËáµÄ¹Ç¼ÜÐÞÊκÍÅäºÏÎï½áºÏÐÞÊÎÁ½ÀàÔöǿϸ°ûתÔ˵ÄÐÞÊη½·¨½øÐÐ×ÛÊö£¬²¢¶ÔÐÞÊÎÐÔëĺËËáϸ°ûתÔËÑо¿ÖдæÔÚµÄÎÊÌâÒÔ¼°Î´À´µÄÑо¿Ç÷ÊÆ¼°ÆäÓ¦ÓÃÌá³öÁ˼û½â¡£

1991Ä꣬µ¤Âó¸ç±¾¹þ¸ù´óѧÉúÎﻯѧ¼ÒNielsenµÈ[1]ͨ¹ý¼ÆËã»úÉè¼Æ£¬Ê×´ÎÌá³öÁËëĺËËá (Peptide nucleic acid£¬PNA)£¬ËüÊÇÒ»ÖÖÈ˹¤ºÏ³ÉµÄDNAºÍRNAÀàËÆÎï¡£ÔÚëĺËËá·Ö×ÓÖУ¬N-(2-°±ÒÒ»ù) ¸Ê°±Ëá½á¹¹µ¥ÔªÍ¨¹ýõ£°·¼üÁ¬½Ó¹¹³É¹Ç¼ÜÒÔÌæ´úºËËá·Ö×ÓÖÐÎìÌÇ-Á×Ëá½á¹¹£¬¼î»ùÔòͨ¹ýÑǼ×ôʼüÓë¹Ç¼ÜÖÙ°±»ùÉϵÄNÏàÁ¬ (ͼ 1)¡£ÕâÖÖÓëÌìÈ»ºËËáÏàËÆµÄ¿Õ¼ä½á¹¹Ê¹µÃPNAÄÜÒÔ¼î»ù»¥²¹Åä¶ÔÔ­ÔòÓëDNA»òRNAÔÓ½»[2]¡£ÓëÌìÈ»ºËËáÏà±È£¬PNA¾ßÓÐÒÔÏÂÓŵ㣺¹Ç¼ÜµÄÈáÈÍÐԺ͵çÖÐÐÔʹÆäÓëDNA»òRNAÔÓ½»µÄÇ׺ÍÁ¦¸ü¸ß[3]£»½á¹¹Öв»º¬°±»ùËá²Ð»ù»òÁ×ËáÎìÌǵ¥Ôª£¬Òò´Ë²»ÊܺËËáø»òµ°°×ø½µ½â£¬ÉúÎïÎȶ¨ÐÔ¸ß[4]£»·ÇÊÖÐÔ¹¹Ïó±ãÓÚµ¥ÌåºÏ³ÉºÍ´¿»¯[5]£»¹Ç¼Üº¬Öظ´µÄõ£°·¼ü½á¹¹£¬Òò´Ë¿ÉÒÔʹÓùÌÏàºÏ³É·½·¨ºÏ³É¹Ñ¾ÛÎï[6]¡£

ͼƬ
ͼ1 ͼ1 PNA (a) ºÍDNA (b) µÄ¹Ç¼Ü½á¹¹
È»¶ø£¬Î´ÐÞÊÎPNAÔÚÓ¦ÓÃʱÈÔ´æÔÚÒÔÏÂȱµã£ºÇ×Ë®ÐԵĽṹºÜÄÑ͸¹ýϸ°ûĤ£¬µ¼ÖÂϸ°ûÉãÈë²î£»Óë°ÐÐòÁнáºÏ²»¾ß±¸·½ÏòÐÔ£»µçÖÐÐÔÒýÆðPNA·Ö×Ó×Ô¾Û¼¯µ¼ÖÂË®ÈÜÐÔ²î[7]¡£ÆäÖУ¬PNAµÄ¿çϸ°ûĤתÔËÄÑÌâ³ÉΪӦÓõÄ×î´óÕϰ­£¬¿çĤתÔËÀ§ÄÑʹPNAÄÑÒÔµ½´ïϸ°ûÄÚ£¬Ó°ÏìÁËÓë°ûÄڰеãµÄ½áºÏ£¬½µµÍÁËÉúÎïÀûÓöÈ[8]¡£Òò´Ë£¬ÔöÇ¿PNAµÄϸ°ûÉãÈëˮƽÊǹ¤³ÌÓ¦ÓõĹؼüÖ®Ò»¡£Æù½ñ£¬ÔÚÕâ·½ÃæÈ¡µÃÒ»¶¨³ÉЧµÄ·½·¨¿É·ÖΪÒÔÏÂ3Àà¡£µÚÒ»£¬ÔçÆÚÑо¿Ö÷Òª¼¯ÖÐÔÚ¶Ôϸ°ûĤ½á¹¹µÄ¸ÄÔ죬ÈçµçÖ¿׷¨[9]¡¢ÉøÍ¸»¯Ï¸°û·¨[10]£¬¸Ã·½·¨»ùÓÚ¶Ô°Ðϸ°ûĤ½á¹¹µÄÐÞÊΣ¬ÄÑÒÔÊÊÓÃÓÚPNA¹¤³Ì»¯Ó¦Óᣵڶþ£¬¶ÔPNAתÔËÐÎʽ½øÐиÄÔ죬ÈçÓëDNAЭͬתÔË[11]¡¢Ö¬ÖÊÌå°üÂñ[12]¡¢ÄÉÃ×Á£Ð­ÖúתÔË[13]£¬ÆäÖУ¬²ÉÓÃÓëÄÉÃ×Á£¹²¼ÛÁ¬½ÓÈ¡µÃÁ˽ϺõijÉЧ¡£BertucciµÈ[14]½«PNA¹²¼ÛÁ¬½Óµ½LÐÍ·ÐʯÄÉÃ×¾§Ìå±íÃæ£¬²¢ÓÃÉúÎï¿É½µ½âµÄ¾Û-L-Àµ°±Ëá½øÐаüÒ£¬Ñ¡ÓÃHelen Laneϸ°û (HeLa) ¿¼²ìתÔËÇé¿ö£¬½á¹û±íÃ÷£¬¸ÃÁ¬½Ó¸´ºÏÎïµÄϸ°ûÉãÈ¡ÂÊÃ÷ÏÔÔö¼Ó¡£MaµÈ[15]½«PNAÓë¶à¿×¶þÑõ»¯¹èÄÉÃ׿ÅÁ£ (Mesoporous silica nanoparticles£¬MSNP) ͨ¹ý¶þÁò¼ü¹²¼ÛÁ¬½ÓµÃµ½PNA-SS-MSNPÁ¬½Ó¸´ºÏÎÔÚMSNPЭÖúתÔËÏ£¬¸´ºÏÎïÒÔÄÚÍÌ·½Ê½½øÈëHeLaϸ°û£¬Ëæºó°ûÄÚ¸ßŨ¶ÈµÄ¹Èë׸ÊëĶÏÁѶþÁò¼ü£¬Êͷųö·´ÒåPNA£¬²¢ÓÐЧ³ÁĬBϸ°ûÁܰÍÁö-2 (B-cell lymphoma 2£¬Bcl-2) µ°°×±í´ï¡£McNeerµÈ[16]½«¾ÛºÏÎïÄÉÃ×Á£×÷ÎªÔØÌå¼ÓÔØÈý¾ÛÌåPNA£¬¸ÃÄÉÃ×Á£ÄÜ˳ÀûתÔËÖÁÄÒÐÔÏËά»¯Ö§Æø¹ÜÉÏÆ¤Ï¸°û (Cystic fibrosis bronchial epithelial cells£¬CFBE) ÄÚ£¬²¢Ð£ÕýF508del»ùÒòÍ»±ä¡£µÚÈý£¬¶ÔPNA½á¹¹½øÐл¯Ñ§ÐÞÊΡ£»¯Ñ§ÐÞÊη¨¾ßÓвÙ×÷·½±ã¡¢ÐÎʽ¶àÑù¡¢ÊʺÏÌåÄÚÑо¿µÈÓŵ㣬Òò´Ë±¸ÊܹØ×¢¡£±¾ÎĽáºÏ±¾ÊµÑéÊÒÑо¿³É¹û£¬¶Ô½üÊ®ÄêÀ´ºÏ³ÉµÄ¸÷ÖÖÔöǿϸ°ûתÔËÐÔÄܵĻ¯Ñ§ÐÞÊÎPNA½øÐÐ×ÛÊö£¬×ܽáÁËÐÞÊÎÐÔëĺËËáϸ°ûתÔËÑо¿ÖдæÔÚµÄÎÊÌ⣬²¢¶ÔδÀ´µÄÑо¿Ç÷ÊÆ¼°ÆäÓ¦ÓÃÌá³öÁ˼û½â¡£

1 ¹Ç¼ÜÐÞÊÎÐÍPNAµÄϸ°ûתÔË

×ÔPNAÌá³öÒÔºó£¬¶ÔÆä½á¹¹µ¥Ôª½øÐл¯Ñ§ÐÞÊγÉΪÑо¿ÖصãÖ®Ò»¡£PNA½á¹¹µ¥ÔªµÄÐÞÊοɷÖΪ¼î»ùµÄÌæ»»ºÍ¹Ç¼Ü½á¹¹µÄ¸ÄÔì¡£¶àÊýÇé¿öÏ£¬¼î»ùÌæ»»»áÓ°ÏìPNAµÄÔÓ½»ÐÔÄÜ£¬´Ó¶ø½µµÍPNAµÄÉúÎï»îÐÔ¡£Ä¿Ç°¼î»ùÌæ»»Ñо¿Ö÷ÒªÊÇΪÁËÔÚPNAÖÐÒýÈëÓ«¹â»ùÍÅ£¬MatarazzoµÈ[17]ÓÃ߹ऻù°±»ùÄòà×à¤Ìæ»»ÆÕͨ¼î»ù£¬¸Ã»ùÍżȱ£ÁôÁËÒ»¶¨µÄÔÓ½»ÄÜÁ¦£¬Í¬Ê±ÓÖ¾ßÓÐÓ«¹âÌØÐÔ¡£Æù½ñ£¬Óйؼî»ùÌæ»»ÐÍPNAµÄϸ°ûתÔËÑо¿²»¶à£¬BischofµÈ[18]Óú¬îÉÒ»Ñõ»¯Ì¼ÊÍ·Å·Ö×Ó (CO-releasing molecules£¬CORMs) Ìæ»»ÆÕͨ¼î»ù£¬ÔڸûùÍŵÄЭÖúÏ£¬PNAתÔËЧÂÊÌá¸ß£¬¶øÇÒ×ÔÉíµÄCORMÌØÐÔ²»»á¸Ä±ä¡£ÔÚPNA½á¹¹µ¥ÔªÐÞÊÎÖУ¬¹Ç¼ÜÐÞÊÎÊǸÄÉÆPNAϸ°ûתÔËÐÔÄܵÄÖ÷Òª´ëÊ©¡£¹Ç¼ÜÐÞÊÎÖ¸¶ÔPNAµÄN-(2-°±ÒÒ»ù) ¸Ê°±Ëáµ¥Ôª½á¹¹½øÐиÄÔ죬¹Ç¼ÜÐÞÊÎPNAÔÚÔö¼ÓË®ÈÜÐÔºÍÔöÇ¿ÔÓ½»ÐÔÄÜ·½ÃæÈ¡µÃÁËÒ»¶¨µÄ³É¹¦£¬¶øÇÒ£¬²¿·Ö¹Ç¼ÜÐÞÊÎPNA»¹¾ß±¸ÖîÈç¹âѧÐÔÄÜ¡¢×Ô×é×°µÈÌØÊâÓÅµã£¬ÍØÕ¹ÁËPNAµÄÓ¦Ó÷¶Î§[19, 20]¡£ÔڹǼÜÐÞÊη¨ÖУ¬¹Ø¼üÊDz»ÄÜÓ°ÏìÔÓ½»ÐÔÄÜ£¬PNAÓëDNA»òRNAµÄÌØÒìÐÔ½áºÏÊÇPNA´ó¶àÊýÓ¦ÓõÄǰÌáÌõ¼þ¡£HyrupµÈ[21]Ö¸³öÎÞÂÛÊǸıäÁ½¸öõ£°·¼üÖ®¼äµÄ¹Ç¼Ü³¤¶È£¬»¹ÊǸıä¼î»ùÓë°±»ùÖ®¼äµÄ¹Ç¼Ü³¤¶È¶¼»á½µµÍPNAÓëDNA»òRNAµÄÌØÒìÐÔ½áºÏÄÜÁ¦¡£Òò´Ë£¬ÎÒÃÇÈÏΪPNAµÄ¹Ç¼ÜÐÞÊÎÓ¦×ñÑ­²»¸Ä±ä»ù±¾¿Õ¼ä¹¹Ð͵ÄÔ­Ôò£¬¿ÉÒÔ²ÉÈ¡¹Ç¼ÜÈ¡´úÐÞÊλòÕßÌæ»»¹Ç¼ÜÔ­×Ó¹¹³ÉµÈÐÞÊη½·¨¡£

1.1 È¡´ú¹Ç¼ÜÉÏHÔ­×Ó

PNA¹Ç¼ÜÉÏÓÐ3ÖÖÀàÐÍÑǼ׻ù£¬Í¨¹ý¸Ä±äÑǼ׻ùÉÏÈ¡´ú»ùÍŵÄÖÖÀ࣬¿ÉÒԵõ½²»Í¬ÀàÐ͵ÄPNA¡£ÔçÆÚÑо¿ÒÔ²»Í¬¦Á°±»ùËáΪÆðʼԭÁÏ£¬ºÏ³ÉÁ˶àÖֹǼÜÐÞÊÎÐÍPNA£¬NielsenµÈ[22]Ñо¿ÁËÒÔÀµ°±Ëᡢ˿°±Ëá¡¢¹È°±Ëá¡¢Ì춬°±Ëá¡¢ÒìÁÁ°±Ëá²Ð»ùΪ¹Ç¼ÜµÄÐÞÊÎÐÍPNAµÄÔÓ½»ÌØÐÔ£¬·¢ÏÖÖ»ÓÐD-Àµ°±ËáµÄTmÖµÉý¸ß£¬ÆäËûPNAµÄTmÖµ¾ùϽµ¡£Ä¿Ç°£¬¶ÔÑǼ׻ùÉÏHÔ­×ÓµÄÈ¡´úÊÇPNA¹Ç¼ÜÐÞÊεÄÖØÒª·½·¨¡£MaisonµÈ[23]²ÉÓÃÎÚ¼ª·´Ó¦ (Ugi reaction)£¬ÒÔ°·¡¢ôÈËá¡¢Òìëæ¡¢È© (»òͪ) 4ÖÖ×é·ÖΪԭÁÏ·¢ÉúËõºÏ·´Ó¦£¬Í¨¹ý±ä»»¸÷×é·Ö½á¹¹¿ÉÒÔÒ»²½ºÏ³É¸÷ÖÖÀàÐ͵ĹǼÜÈ¡´úPNA (ͼ 2)¡£ÕâÖÖÈ¡´úÐÞÊÎʹµÃPNAµ¥Ìå³ÉΪÊÖÐÔ·Ö×Ó£¬¶øÇÒ¸÷¹âѧÒì¹¹ÌåµÄË®ÈÜÐÔ¡¢ÔÓ½»ÐÔÄܵÈÍùÍùÓвîÒ죬ͨ¹ýÊʵ±É¸Ñ¡£¬ÄÜÕÒµ½ÐÔÄܸü¼ÓÓÅÒìµÄPNA¡£MitraµÈ[24]Óð±¼×»ù (Aminomethylene£¬am) È¡´úPNA¹Ç¼ÜÖЦÁλºÍ¦ÃλµÄHÔ­×Ó£¬µÃµ½Á˦Á-S-amPNA¡¢¦Á-R-amPNAºÍ¦Ã-S-amPNA 3ÖֹǼÜÐÞÊÎÐÍPNA£¨Í¼ 3A-C£©¡£Í¨¹ýÓëÌØÒìÐÔ½áºÏµÄcDNAÔÓ½»£¬·¢ÏÖÓëδ¾­ÐÞÊεÄPNAÏà±È£¬¦Á-S-amPNA¡¢¦Á-R-amPNAºÍ¦Ã-S-amPNAµÄTmÖµ¶¼ÏàÓ¦Ôö´ó£¬×î¸ßÔö¼Ó10 ¡æ£¬Õâ±íÃ÷¸Ã½á¹¹ÓëDNAÌØÒìÐÔ½áºÏÄÜÁ¦ÔöÇ¿¡£Ëæºó£¬Ñ¡ÓÃHeLaϸ°ûÑо¿ÁËam-PNA½øÈëϸ°ûµÄÄÜÁ¦¡£½á¹û±íÃ÷£¬3ÖÖÐÞÊÎÐÍam-PNAµÄϸ°ûÉãÈëˮƽ¶¼±Èδ¾­ÐÞÊεÄPNA¸ß£¬¶øÇÒ£¬Æäϸ°ûתÔËÄÜÁ¦¾ßÌå±íÏÖΪ£º¦ÃλÐÞÊδóÓÚ¦ÁλÐÞÊΣ¬R¹¹ÐÍ´óÓÚS¹¹ÐÍ¡£KumarµÈ[25]Óð±±û»ùÈ¡´úPNA¹Ç¼ÜÖЦÃλµÄHÔ­×Ó£¬µÃµ½ÁËC¦Ã-°±»ù±ûÏ© PNA (amp-PNA) (ͼ 3D)¡£ºÍÌØÒìÐÔDNAµÄÔÓ½»ÊµÑé±íÃ÷£¬Óëδ¾­ÐÞÊεÄPNAÏà±È£¬ÆäTmÖµÔö´ó£¬¶øÇÒÆäÔÓ½»ÐÔÄÜÓÅÓÚ̼Á´³¤¶ÈΪ4µÄ°±¶¡»ùPNA¡£ÔÚÈËÈéÏÙ°©Ï¸°û (Michigan cancer foundation-7£¬MCF-7) תÔËʵÑéÖз¢ÏÖamp-PNAÄܸßЧ½øÈë¸Ãϸ°û£¬²¢¾Û¼¯ÔÚϸ°ûºË¸½½ü¡£

ͼƬ
ͼ2 Ugi 4CC·¨ºÏ³ÉPNAµ¥Ìå
ͼƬ
ͼ3 am-PNAºÍamp-PNAµÄ»¯Ñ§½á¹¹
1.2 ¹Ç¼ÜÉÏÒýÈë»·×´½á¹¹

½«»·×´½á¹¹ÒýÈëPNAÊǵõ½¹Ç¼ÜÐÞÊÎÐÍPNAµÄÖØÒª·½·¨Ö®Ò»£¬Ö÷ҪѡÔñ½ÏÎȶ¨µÄÎåÔª»·ºÍÁùÔª»·¡£ÆäÖУ¬´øÎåÔª»·µÄPNAÒòÆä½á¹¹½ÏºÃµØÄ£ÄâÁËDNAÖÐÎìÌÇ»·£¬Êܵ½ÈËÃǵÄÖØÊÓ¡£ºÏ³Éʱ¿ÉÒÔÑ¡Ôñ×ÔÉíº¬ÓÐÎåÔª»·½á¹¹µÄ¸¬°±Ëá×÷ΪÆðʼԭÁÏ¡£SuparppromµÈ[26]ºÏ³ÉÁ˹ǼܽṹΪ¸¬°±õ£»ù-2-°±»ù»·ÎìôÈËá (Prolyl-2- aminocyclopentanecarboxylic acid£¬ACPC) µÄACPC-PNA (ͼ 4A)£¬ÕâÖÖ´øÓÐßÁ¿©Íé»ùµÄPNA¾ßÓкÜÇ¿µÄ¸ÕÐÔ½á¹¹ÌØÐÔ¡£ÆäÖй¹ÐÍΪ (1S£¬2S)-ACPC-PNA¾ßÓÐÁ¼ºÃµÄÔÓ½»ÐÔÄÜ£¬TmÖµ´óÓÚ85 ¡æ£¬¸ßÓÚÏàÓ¦DNA-DNAµÄTmÖµ¡£MerinoµÈ[27]ºÏ³ÉÁ˺¬ÓÐÒì¶ñßòÍé½á¹¹µÄIsoxazolidinyl PNA (Isox-PNA) (ͼ 4B)£¬¸Ã¹Ç¼Ü½á¹¹¿ÉÒÔÖÊ×Ó»¯£¬ÓÐÀûÓÚPNAµÄϸ°ûתÔË£¬Í¬Ê±»¹¾ßÓÐÁ¼ºÃµÄË®ÈÜÐÔ¡£Ä¿Ç°£¬¶Ô»·×´½á¹¹PNAµÄÑо¿Ö÷񻃾¼°Ìá¸ßË®ÈÜÐÔºÍÔÓ½»ÐÔÄÜ£¬ÔÚϸ°ûתÔË·½Ã滹ȱ·¦Ñо¿Êý¾Ý¡£

ͼƬ
ͼ4 ¹Ç¼ÜÖк¬Óл·×´½á¹¹µÄPNA
1.3 Ìæ»»¹Ç¼ÜÉÏCÔ­×Ó

¶Ô¹Ç¼ÜCÔ­×ÓÌæ»»¾ßÓв»¸Ä±äPNA¹¹Ð͵ÄÓŵ㣬ͨ³£²»»á½µµÍPNAµÄÔÓ½»ÐÔÄÜ¡£KitamatsuµÈ[28]ºÏ³ÉÁË´øÓÐßÁ¿©»·µÄº¬ÑõßÁ¿©ÍéPNA

(POPNA) ºÍº¬°±»ùßÁ¿©ÍéPNA (PAPNA) (ͼ 5)¡£ÔÚPOPNAÖУ¬OÔ­×ÓÌæ»»CÔ­×Ó£¬¼´ÃѼü´úÌæÑǼ׻ù£¬ÃѼü¹Ç¼ÜÈáÈÍÐÔ¸üºÃ£¬ÓëDNA»òRNA½áºÏÀι̣¬ÆäË®ÈÜÐÔÒ²ÏàÓ¦Ìá¸ß¡£ÔÚÖйú²ÖÊóÂѳ²Ï¸°û (CHO) ÖеÄÎüÊÕʵÑé±íÃ÷£¬Óë¸Ê°±Ëá¹Ç¼ÜPNAÏà±È£¬ÆäË®ÈÜÐÔ¡¢ÔÓ½»ÌØÐÔÒÔ¼°Ï¸°ûÉãÈ¡¶¼µÃµ½Á˸ÄÉÆ¡£ÔÚPAPNAÖУ¬NÔ­×ÓÌæ»»CÔ­×Ó£¬¼´Êå°±»ù´úÌæÑǼ׻ù£¬Êå°±»ù¿ÉÖÊ×Ó»¯£¬ÆäËù´øµÄÑôÀë×ÓµçºÉÓÐÀûÓÚ¿çϸ°ûĤתÔË¡£CHOϸ°ûתÔËʵÑéÑо¿±íÃ÷£¬ÓÉPAPNA×é³ÉµÄ¹Ñ¾ÛPNAϸ°ûÉãÈëЧÂʸߣ¬µ«ÓëDNAºÍRNAµÄÔÓ½»ÌØÒìÐԲ¶øÓÉPOPNA×é³ÉµÄ¹Ñ¾ÛPNAϸ°ûÉãÈëЧÂʵ͡£½«2¸öµ¥ÔªPAPNAºÍ7¸öµ¥ÔªPOPNA¾ÛºÏÐγɻìºÏ¹Ñ¾ÛPNA£¬·¢ÏÖÔÓ½»ÌØÒìÐÔºÍϸ°ûÉãÈëЧÂʾù½ÏºÃ¡£

ͼƬ
ͼ5 POPNA (a) ºÍPAPNA (b) µÄ»¯Ñ§½á¹¹
2 PNAÁ¬½ÓÎïµÄϸ°ûתÔË

PNAÁ¬½ÓÎï (PNA conjugates) ÊÇÖ¸½«PNAºÍÅäÌåÖ±½Ó¹²¼Û½áºÏ£¬»òÕßͨ¹ýÖнé»ùÍŽ«Á½Õß¹²¼ÛÁ¬½Ó£¬µÃµ½PNA-ÅäÌ帴ºÏÎï¡£KoppelhusµÈ[29]ÈÏΪ£¬PNAʵÏÖ¹¤³ÌÓ¦ÓõÄǰÌáÖ®Ò»ÊÇÆä×ÔÉí·Ö×ÓÄܸßЧͨ¹ýϸ°ûĤ¡£ÎÒÃÇÈÏΪÖîÈçϸ°û΢עÉä·¨¡¢µç´©¿×·¨ºÍµçÉøÍ¸·¨ËäȻתÔËЧÂʽϸߣ¬µ«ÔÚÌåÄÚʹÓÃÊÜÏÞ£¬²»ÊʺÏÁÙ´²Ó¦Ó᣶ÔPNA·Ö×ӽṹµÄÕûÌåÐÞÊΣ¬ÓÈÆäÊÇѰÕÒºÏÊʵÄÅäÌ壬֯±¸¿çĤתÔËÐÔÄÜÓÅÔ½µÄPNAÁ¬½ÓÎïÊÇÒ»ÖÖÓÐЧµÄÊֶΡ£ÒÔÅäÌå¹²¼ÛÐÞÊÎÖÆ±¸Á¬½ÓÎïµÄ·½·¨²»½ö¾ß±¸¸ßЧµÄϸ°û´«µÝÐÔÄÜ£¬¶øÇÒÔÚÔÓ½»ÐÔÄÜ¡¢Ï¸°û¶¾ÐԵȷ½Ãæ¾ßÓÐÒ»¶¨ÓÅÊÆ£¬¾ßÓй¤³ÌÓ¦ÓõÄDZÁ¦¡£½üÄêÀ´£¬¶ÔPNA·Ö×Ó½øÐÐÕûÌåÐÞÊΣ¬Ñ°ÕÒºÏÊʵÄÅäÌ壬ȡµÃÁËһЩ³É¹¦µÄÑо¿³É¹û£¬ÕâÒ²¿ÉÄÜÊǽñºó½«PNA¹¤³Ì»¯¿ª·¢Ñо¿µÄÒ»¸öÇ÷ÊÆ¡£

2.1 PNA-CPPÁ¬½ÓÎï

Ŀǰ£¬ÔÚÖÖÀàÖÚ¶àµÄPNAÁ¬½ÓÎïÖУ¬Ê¹ÓÃ×î¹ã·ºµÄÊÇPNA-CPP¡£Ï¸°û´©Í¸ëÄ (Cell penetrating peptide£¬CPP) ÊÇÒ»ÀàÄÜЯ´ø¸÷ÖÖÀàÐÍ´ó·Ö×ÓÎïÖÊ´©¹ýϸ°ûĤ£¬½øÈëϸ°ûÄÚ²¿µÄ¶àëÄ¡£Ò»°ãΪ´øÕýµçºÉµÄ³¤¶Ì²»Ò»µÄ¶ÌëÄ£¬¸»º¬¾«°±Ëá¡¢Àµ°±ËáµÈ¼îÐÔ°±»ùËá²Ð»ù£¬ÕýµçºÉÌØÐÔÓÐÖúÓÚÓëϸ°û±íÃæµÄÌØ¶¨Î»µã½áºÏ[30]¡£CPP×÷ΪÒýµ¼ÎïÖÊÒѹ㷺ӦÓÃÓÚDNA¡¢RNAÒÔ¼°Ò©Îï·Ö×ӵĿçĤתÔË£¬½è¼øÕâЩ¾­Ñ飬½«CPPÒýÈëPNA´«µÝÌåϵ£¬È¡µÃÁ˽ϺõijÉЧ¡£Ï¸°û¶ÔPNA-CPP¹²¼ÛÁ¬½ÓÎïÖ÷Ҫͨ¹ýÀàËÆ°ûÍ̵ÄÄÚ»¯×÷Óã¬Ê¹PNA³É¹¦½øÈë°û½¬µÄÅÝÄÒÖС£±í 1ºÍ±í 2×ܽáÁ˽üÊ®ÄêÀ´ÔÚPNAתÔËÌåϵÆÕ±é²ÉÓÃÇÒÓÐЧµÄCPP£¬Ö÷ÒªÓÐÒÔÏÂ6ÖÖ£º1) µ¥¾Û¾«°±ËáºÍÀµ°±ËáÀà (Simple oligoarginines and oligolysines)£»2) HIV·´Ê½¼¤»îµ°°× (HIV transactivator protein£¬Tat)£»3) ºË¶¨Î»ÐòÁÐ (Nuclear localization signal£¬NLS)£»4) (KFF)3K£»5) M918£»6) ÐźÅëÄ (Signal peptide)¡£

±í1 ÓÃÓÚתÔ˵ÄPNA-CPPÁ¬½ÓÎï
ͼƬ
±í2 CPPµÄ°±»ùËáÐòÁÐ
ͼƬ
Ñо¿±íÃ÷£¬¸÷ÖÖ¸»º¬¾«°±ËáºÍÀµ°±ËáµÄ¶àëľßÓÐϸ°ûתÔË»îÐÔ£¬ËäÈ»ËüÃǵÄÒ»¼¶½á¹¹ºÍ¶þ¼¶½á¹¹¸÷Ò죬ÆäתÔË»úÀí¼È²»Í¬ÓÚϸ°ûĤÄÚÍÌ×÷Óã¬Ò²²»Í¬ÓÚϸ°û±íÃæÊÜÌå½áºÏ×÷ÓÃ[40]¡£Ò»°ãÈÏΪ£¬°±»ùËá²Ð»ùÊýÄ¿¶ÔPNAתÔË»îÐÔÓÐÏÔÖøÓ°Ï죬¾ßÓнϺÃתÔËЧÂʵIJлùÊýΪ5µ½12¸ö¡£BendifallahµÈ[33]¿¼²ìÁ˾«°±Ëá²Ð»ùÊýµÄÓ°ÏìÇé¿ö£¬·¢ÏÖPNA-Arg9Á¬½ÓÎïµÄϸ°ûתÔËЧÂÊ´óÓÚ Arg7ºÍ Arg8£¬ËûÃÇÈÏΪÊʵ±Ôö¼Ó°±»ùËá²Ð»ùÊý¿ÉÒÔÌá¸ßPNA-ArgµÄϸ°ûÉãÈë¡£ÁíÒ»ÖÖ³£Óõĵ¥¾Û¶àëÄÊǾÛÀµ°±ËᣬAlbertshoferµÈ[32]·¢ÏÖÁ¬½Ó°Ë¾ÛL-Àµ°±ËáµÄPNAÄܸßЧͨ¹ýÊóBCL1ϸ°ûĤ¡£1988Ä꣬ÈËÃÇÊ״η¢ÏÖÁËTat·´Ê½¼¤»îµ°°×´©Í¸Ï¸°ûĤµÄ¹¦ÄÜ£¬Ö®ºó±»Ó¦ÓÃÓÚÖîÈç¦Â-°ëÈéÌÇÜÕø¡¢À±¸ù¹ýÑõ»¯ÎïøµÈ¸÷ÖÖ´ó·Ö×ÓÎïÖʵĿçĤתÔË[41]¡£FoliniµÈ[34]½«PNAÓëTat¹²¼ÛÁ¬½Ó£¬·¢ÏÖÁ¬½ÓÎïÄÜ˳Àû½øÈëDU145°©Ï¸°û£¬²¢Óë°ûÄÚÌØ¶¨mRNAÌØÒìÐÔ½áºÏ£¬¸ÃÁ¬½ÓÎïÓëÆäËû´«µÝ·½·¨Ïà±ÈÓÐЧµØÌá¸ßÁËPNAµÄÉúÎïÀûÓöȡ£SuµÈ[35]²ÉÓùÌÏàºÏ³É·¨ºÏ³ÉÁËPNA-AEEA-TatÁ¬½ÓÎ²¢ÒÔŨ¶ÈÒÀÀµ·½Ê½¸ßЧµØ½øÈëÁË3T3ϸ°û¡£NLSÄÜÓëºËÔØÌåÏ໥×÷Óã¬Ö÷ÒªÓ¦ÓÃÓÚ½«´ó·Ö×ÓתÔËÖÁϸ°ûºË¡£ÓÐÑо¿·¢ÏÖNLSÒ²ÄÜ´Ù½øPNAµÄϸ°ûÉãÈëˮƽ£¬Joshi µÈ[36]½«NLS¹²¼ÛÁ¬½Óµ½PNAÉÏ£¬²¢Ñо¿ÁËËüÃǽøÈëϸ¾úºÍ²¸È鶯Îïϸ°ûµÄÇé¿ö£¬·¢ÏÖÁ¬½ÓÎïתÔËЧÂÊÊÇδ¾­ÐÞÊÎPNAµÄ2±¶¡£µ«ÊÇ£¬BendifallahµÈ[33]½«NLSÓëÆäËûÒýµ¼»¯ºÏÎï½øÐбȽϺó·¢ÏÖPNA-NLSµÄתÔËЧÂʲ»ÊǺܺá£(KFF)3KÒ²ÊÇÒ»ÖÖ³£ÓõÄÒýµ¼»¯ºÏÎï¡£GhosalµÈ[37]·Ö±ðÑо¿ÁËDÐͺÍLÐ͵Ä(KFF)3KЭÖúPNA½øÈëϸ°ûÇé¿ö£¬·¢ÏÖÖ»ÓÐLÐ͵ÄL((KFF)3K)¾ßÓкܺõÄЧ¹û£¬¶øÍ¬ÑùÐòÁеÄDÐͶàëÄûÓдٽøPNAµÄ¿çĤתÔË¡£M918ÊÇÒ»ÖÖº¬ÓÐ22¸ö°±»ùËá²Ð»ùµÄ¶àëÄ£¬¸»º¬¾«°±Ëá¡£LeeµÈ[38]ÔÚHT-29-lucϸ°ûÖÐÑо¿ÁËPNA-M918Á¬½ÓÎïµÄϸ°ûתÔËÇé¿ö£¬·¢ÏÖ¸ÃÁ¬½ÓÎïÄÜÓÐЧµØ½øÈëϸ°û£¬²¢ÌØÒìÐÔ³ÁĬÏàÓ¦»ùÒò¡£¶øÇÒÔڸߴï25 umol/L Ũ¶ÈÏ£¬M918¼È²»»áËðÉËϸ°ûĤ£¬Ò²²»»á¶Ôϸ°ûÔöÖ³²úÉúÓ°Ï죬·Ç³£ÊʺÏÌåÄÚÓ¦Óá£ÐźÅëÄ¿ÉÒÔÖ±½ÓÒýµ¼µ°°×ÖÊ´©¹ýÕæºËϸ°ûµÄÄÚÖÊÍøÄ¤ºÍÔ­ºËϸ°ûµÄÄÚĤ£¬ÆäÐòÁÐÍùÍù°üº¬ÓÉÊèË®°±»ùËá²Ð»ù¹¹³ÉµÄÊèË®ºË¡£Ñо¿±íÃ÷ÐźÅëĵÄЭÖúתÔË×÷ÓÃÖ÷ÒªÊÇÓÉÓÚÆäÊèË®ÇøÓòºÍϸ°ûĤÉÏË«·Ö×Ó²ãÖ¬ÖʵÄÏ໥×÷Óã¬LiµÈ[39]ÈÏΪÕâÖÖÏ໥×÷ÓÃÒªÇóÐźÅëĵݱ»ùËá²Ð»ùÊýΪ5µ½15¸ö¡£ËûÃǽ«Ò»ÖÖ15¸ö°±»ùËá²Ð»ùµÄÐźÅëļ°Á½ÖÖÀàËÆ¶àëÄ·Ö±ðÁ¬½Óµ½º¬10¸öÐØÏÙà×़î»ùµÄPNAµÄNÄ©¶Ë£¬²¢Ñо¿ÁË3ÖÖÁ¬½ÓÎï½øÈëºìϸ°ûµÄÇé¿ö£¬½á¹û±íÃ÷3ÖÖÁ¬½ÓÎï¶¼ÔöÇ¿ÁËPNAµÄϸ°ûÉãÈëˮƽ£¬¶øÇÒÊ®ÎåëĵÄЭÖúתÔËЧÂÊ×îºÃ£»µ«ÊÇÊ®ÎåëÄÁ¬½ÓÎïµÄË®ÈÜÐԲ¶øÁíÍâÁ½ÖÖÁùëĺÍÊ®ëÄÁ¬½ÓÎïµÄË®ÈÜÐԽϺá£
2.2 PNA-Ç×Ö¬ÐÔÅäÌåÁ¬½ÓÎï
PNAÓëÊèË®ÐÔ»¯ºÏÎï»òÀàÖ¬¹²¼Û½áºÏËùÐγɵÄÁ¬½ÓÎï¾ßÓÐijЩÓÅÒìµÄÌØÐÔ¡£ÀýÈ磬ÔÚPNAµÄNÄ©¶ËÁ¬½ÓÊèË®ÐÔ³¤Ì¼Á´£¬ÔÚCÄ©¶ËÁ¬½Ó°±»ùËá²Ð»ù£¬¸ÃÁ¬½ÓÎï¾ßÓÐÁ¼ºÃµÄÇ×Ë®Ç×ÓÍÐÔ£¬ÓëDNAÔÓ½»Ê±±íÏÖ³ö¸üºÃÌØÒìÐÔ[42]¡£¸ÃÁ¬½ÓÎﻹ¿É×Ô×é×°³ÉÇòÐνºÊø£¬ÔÚÉúÎï´«¸ÐÆ÷¡¢»ùÒòÒ©ÎïµÈ·½Ãæ¾ßÓÐÓ¦ÓÃDZÁ¦[43]¡£¶øÇÒPNA-Ç×Ö¬ÐÔÅäÌåÁ¬½ÓÎïÔÚϸ°ûתÔË·½ÃæÒ²ÏÔʾ³öºÜºÃµÄÐÔÄÜ¡£±í 3×ܽáÁ˽üÊ®ÄêÀ´³É¹¦ÓÃÓÚPNAתÔ˵ÄÇ×Ö¬ÐÔÅäÌ廯ºÏÎï¡£
±í3 ÓÃÓÚתÔ˵ÄPNA-Ç×Ö¬ÐÔÅäÌåÁ¬½ÓÎï
ͼƬ
Ç×Ö¬ÐÔÅäÌåÖÐÊʺÏÓÚϸ°ûתÔ˵ÄÒ»ÀàÎïÖÊÊǾßÓÐÒ»¶¨Ç×Ë®Ç×ÓÍÆ½ºâÖµµÄÀàÖ¬£¬ÔÚ¿çϸ°ûĤתÔËʱ£¬Ç×ˮһ¶Ë³¯Ïò°ûÍâË®ÈÜÐÔ»·¾³£¬¶øÊèˮһ¶ËÔò³¯Ïòϸ°ûĤ²¢Óëϸ°ûĤ×÷Óá£ÕâÖÖÐÞÊεäÐÍ´ú±íÊǵ¨ËáºÍµ¨¹Ì´¼¹²¼ÛÁ¬½ÓPNA£¬¸ÃÁ¬½ÓÎïÔÚÌåÄÚ»¹¾ßÓÐÒ»¶¨µÄ¸ÎÔà°ÐÏò×÷Ó㬾ßÓпª·¢³É¸ÎÔà°ÐÏòÖÆ¼ÁµÄDZÁ¦[44]¡£ShiraishiµÈ[44]½«PNAͨ¹ý°ëçúçêËáõ¥¼üÓ뵨¹Ì´¼»òµ¨Ëá½áºÏ£¬²¢ÔÚHeLa pLuc705ϸ°ûÖжԸ´ºÏÎïµÄ¿çĤתÔËÐÔÄܽøÐвâÊÔ£¬½á¹û±íÃ÷ËùµÃµ½µÄ¸´ºÏÎï¸ßЧµØÍ¨¹ýϸ°ûĤ£¬¶øÇÒPNA-µ¨ËḴºÏÎïµÄË®ÈÜÐÔ¸üºÃ¡£JoshiµÈ[45]½«PNAÓ뵨¹Ì´¼Í¨¹ýÀµ°±ËáÁ¬½Ó£¬ÖƱ¸ÁËÒ»ÖÖ¸ßЧµÄ´Å¹²ÕñÔìÓ°¼Á£¬ÆäתÔËÐÔÄܺÍDNAÌØÒìÐÔ½áºÏÐÔÄܶ¼ºÜºÃ¡£´ËÍ⣬ÊèË®ÐÔ½ÏÇ¿µÄ·¼ÔÓ»·»¯ºÏÎïÓëPNA½áºÏÒ²ÏÔʾ³ö½ÏºÃµÄתÔË»îÐÔ¡£ShiraishiµÈ[46]Ñо¿Á˶àÖÖ·¼ÔÓ»·»¯ºÏÎïÐÞÊÎPNA¼°Æäϸ°ûתÔËÇé¿ö£¬ÕâЩ·¼ÔÓ»·»¯ºÏÎï°üÀ¨ß¹à¤¡¢±½²¢ßäßò¡¢ßÇßò¡¢Ýìõ«¡¢ÜÅ¡¢ß²ßø¡¢ÝÁǶ¼ä¶þµªÔÓ±½¡¢ÑÌËἺ¿É¼î¡¢×ϲ˼²¹¹ÇÖ¬µÈ£¬²¢²ÉÓÃHeLa pLuc705ºÍp53Rϸ°û¿¼²ìÕâЩPNAÁ¬½ÓÎïµÄתÔËÇé¿ö¡£½á¹û±íÃ÷£¬·¼ÔÓ»·»¯ºÏÎï¾ßÓÐÆÕ±éÔöÇ¿PNAתÔ˵ŦÄÜ£¬ÆäÖÐ߹ऺÍÑÌËáÒѿɼîÓëPNAÐγɵÄÁ¬½ÓÎï»îÐÔ×î¸ß¡£µ«ÊÇ£¬Ä¿Ç°»¹²»Çå³þ·¼ÔÓ»·µÄ½á¹¹ÓëתÔË»îÐÔÖ®¼äµÄ¹ØÏµ¡£ÁíÒ»ÀàÊÊÓÃÓÚÔöǿתÔ˵ÄÇ×Ö¬ÐÔÅäÌåÊǾۺÏÎÔÚPNAÖгɹ¦Ó¦ÓõÄÓоÛÁ×Ëáõ¥¡¢¾ÛÒÒÏ©°· (PEI)¡¢¾ÛÒÒ¶þ´¼ (PEG) µÈ¡£ShiraishiµÈ[47]ºÏ³ÉÁ˾ۺ϶ȷֱðΪ3¡¢7¡¢10µÄPNA-¾Û¹È°±õ£°·Á×Ëáõ¥ºÍ¾ÛºÏ¶È·Ö±ðΪ4¡¢5¡¢6µÄPNA-¾ÛÀµ°±Ëá¶þÁ×Ëáõ¥PNAÁ¬½ÓÎ²¢ÔÚHeLa pLuc705ϸ°ûÖнøÐÐתÔËʵÑé¡£½á¹û±íÃ÷£¬½«¾ÛÁ×Ëáõ¥¹²¼ÛÁ¬½ÓÔÚPNAÉÏÏÔÖøµØÔöÇ¿ÁËPNAµÄϸ°ûתÔË£¬¶øÇÒ²»Ó°ÏìÆäÔÓ½»ÌØÒìÐÔºÍÇ׺ÍÐÔ¡£´ËÍ⣬Á×Ëáõ¥µÄÊýÄ¿¶ÔPNAµÄתÔËÓÐÓ°Ï죬Áù¾ÛÀµ°±Ëá¶þÁ×Ëáõ¥Á¬½ÓÎïµÄ»îÐÔ×îÇ¿£¬ÓëδÐÞÊÎPNAÏà±È£¬Æäϸ°ûÉãÈ¡ÂÊ¿ÉÔö¼Ó20±¶¡£BertholdµÈ[48]½«PNAͨ¹ý¶þÁò¼üÓë¾ÛÒÒÏ©°·Á¬½ÓµÃµ½PNA-PEI¸´ºÏÎ²¢ÔÚHeLa pLuc705ϸ°ûÖнøÐÐϸ°û´«µÝʵÑ飬½á¹û±íÃ÷£¬PEI¿ÉÒÔ×÷ΪPNAתÈëϸ°ûµÄ¸ßЧÒýµ¼Î¶øÇÒ²»ÊܰûÄÚÈÜøÌåµÄÓ°Ïì¡£
ÉÏÊöÇ×Ö¬ÐÔÅäÌåÖУ¬ÖîÈ絨¹Ì´¼¡¢¾ÛÁ×Ëáõ¥¡¢PEI¡¢PEGµÈ¶¼ÊôÓÚÑôÀë×ÓÐÍתÔ˽éÖÊ¡£LloveraµÈ[49]Ö¸³öÑôÀë×ÓÐÍÁ¬½ÓÎïÓëϸ°ûĤ±íÃæÇ׺ÍÁ¦Ç¿£¬¶øPNAϸ°ûתÔËЧÂÊÓëϸ°û±íÃæPNAŨ¶ÈÃÜÇÐÏà¹Ø£¬ÕâÊÇÉÏÊöÅäÌå¾ßÓиßЧתÔËÐÔÄܵÄÖØÒªÔ­ÒòÖ®Ò»¡£Í¬Ê±ÎÒÃÇ·¢ÏÖ£¬Ç°ÎÄËùÊöµÄPAPNA¡¢Isox-PNA¡¢am-PNA¡¢amp-PNAÒÔ¼°CPP¶¼¾ßÓдøÕýµçºÉÐÔÖÊ£¬ÆäתÔËÐÔÄÜÒ²Óë×ÔÉíËù´øÕýµçºÉÏà¹Ø¡£Òò´ËÎÒÃÇÈÏΪ£¬ÔÚ½ñºóºÏ³ÉPNAе¥ÌåºÍѰÕÒÐÂÅäºÏÎïÖУ¬ÎªÁËÌá¸ßPNAתÔËÐÔÄÜ£¬¿ÉÒÔ¿¼Âǽ«ÒýÈë´øÕýµçºÉ»ùÍÅ×÷ΪһÖÖÓÐЧµÄ´ëÊ©¡£
2.3 PNA-¹¦ÄÜÐÔÅäÌåÁ¬½ÓÎï
½üÄêÀ´£¬½«PNA¿ª·¢³É»ùÒòÒ©ÎïÊÇÑо¿ÈȵãÖ®Ò»£¬È»¶øµ¼ÖÂPNA³ÉÒ©ÐÔ²îµÄ×î´óÕϰ­ÒÀÈ»ÊÇϸ°ûתÔËÄÑÌâ¡£½«PNAÓëºÏÊʵľßÓÐÒ©Àí»îÐԵŦÄÜÐÔÅäÌå¹²¼ÛÁ¬½ÓÊÇPNAÒ©Î↑·¢ÖеÄÒ»Öֳɹ¦³¢ÊÔ¡£PNA-¹¦ÄÜÐÔÅäÌåÁ¬½ÓÎïµÄ³É¹¦Éè¼Æ²»½ö¸ÄÉÆÁËPNAµÄϸ°ûÉãÈëˮƽ£¬Í¬Ê±Ò²½«¹¦ÄÜÐÔÅäÌ廯ºÏÎïµ¼Èëϸ°û£¬ÊµÏÖPNAºÍ¹¦ÄÜÐÔÅäÌåË«ÖØÖÎÁÆ×÷Ó᣸ÃÁ¬½ÓÎïÖУ¬ÅäÌå²»½ö½ö¾ßÓÐЭÖúתÔ˵Ä×÷Ó㬻¹ÄÜ·¢»Ó×ÔÉíÒ©Àí»îÐÔ¡£±í 4×ܽáÁ˽üÄêÀ´Ñо¿µÄ¾ßÓÐÔöÇ¿PNAתÔ˵ŦÄÜÐÔÅäÌ廯ºÏÎï¡£
±í4 ÓÃÓÚתÔ˵ÄPNA-¹¦ÄÜÐÔÅäÌåÁ¬½ÓÎï
ͼƬ
±¾ÊµÑéÊÒÔÚPNA-¹¦ÄÜÐÔÅäÌåÁ¬½ÓÎï·½Ãæ×öÁËһЩÑо¿¹¤×÷£¬Íõ½¨»ª[50, 51]Ñо¿ÁËPNAÓë·úÄáÐÁºÍ°¢Ë¾Æ¥ÁֵĹ²¼ÛÁ¬½ÓÎïµÄºÏ³É·½·¨£¬
ËùµÃµ½µÄÁ½ÖÖÁ¬½ÓÎï¾ßÓÐÁ¼ºÃµÄϸ°ûתÔËÐÔÄÜ¡£·úÄáÐÁÊÇÒ»ÖÖ·ÇçÞÌ忹Ñ×½âÈÈÕòÍ´Ò©£¬Ö÷ÒªÖÎÁƲ¡¶¾ÐÔ¸ÐȾÒýÆðµÄÖíÎÞÃû¸ßÈÈ×ÛºÏÕ÷ºÍ¼±ÐÔ¸ßÈÈÑ×Ö¢¡£±¾ÊµÑéÊÒÖÆ±¸µÄPNA-¸¥ÄáÐÁÁ¬½ÓÎïÔÚÓÃÁ¿Îª2 mg/kgʱ£¬×ÐÖíµÄÌåνµµÍֵΪ0.56 ¡æ£»¶øµ¥¶ÀʹÓø¥ÄáÐÁÓÃÁ¿Îª4 mg/kgʱ£¬×ÐÖíµÄÌåνµµÍֵΪ0.57 ¡æ£»µ¥¶ÀʹÓÃPNAÓÃÁ¿Îª10 mg/kgʱ£¬×ÐÖíµÄÌåνµµÍֵΪ0.74 ¡æ¡£PNAÓë·úÄáÐÁ¹²¼ÛÁ¬½ÓËùºÏ³ÉµÄÁ¬½ÓÎï¶ÔÖí¸ßÈȲ¡»ìºÏ¸ÐȾÒýÆðµÄ¼²²¡¾ßÓÐÏÔÖøÖÎÁÆÐ§¹û£¬¶øÇÒЧ¹û±Èµ¥¶ÀʹÓÃPNA»òÕß·úÄáÐÁºÃ¡£°¢Ë¾Æ¥ÁÖÊÇÒ»ÖÖÀúÊ·ÓÆ¾ÃµÄ½âÈÈÕòÍ´Ò©£¬¾ßÓнâÈÈ¡¢ÕòÍ´¡¢¿¹Ñס¢¿¹·çʪ¡¢¿¹ÑªÐ¡°åÄý¼¯ÒÔ¼°Ìá¸ßÃâÒßÁ¦µÈÒ©Àí×÷Ó᣶¯ÎïʵÑéÑо¿±íÃ÷£¬·Ö±ð½«°¢Ë¾Æ¥ÁÖ¡¢PNAºÍPNA-°¢Ë¾Æ¥ÁÖÁ¬½ÓÎï¸øÒ©4Öܺó£¬ÌåÄÚ°×ϸ°ûˮƽ·Ö±ðΪ (22.9¡À3.7)¡Á109/L¡¢(23.1¡À4.6)¡Á109/LºÍ(26.2¡À2.9)¡Á109/L£»ÃâÒßÇòµ°°×GŨ¶È·Ö±ðΪ (53.69¡À8.97) mg/mL¡¢(47.12¡À4.53) mg/mL¡¢(62.36¡À9.58) mg/mL£»³¬Ñõ»¯ÎïÆç»¯Ã¸Å¨¶È·Ö±ðΪ(23.99¡À1.26) ¦Ìg/mL¡¢(18.02¡À2.45) ¦Ìg/mL¡¢(29.60¡À1.78) ¦Ìg/mL¡£PNA-°¢Ë¾Æ¥ÁÖÁ¬½ÓÎïÄÜÃ÷ÏÔÌá¸ßÉúÎïÌåÄÚ°×ϸ°û¡¢ÃâÒßÇòµ°°×GºÍ³¬Ñõ»¯ÎïÆç»¯Ã¸Ë®Æ½£¬¿ÉÓÃÓÚÖÆ±¸ÃâÒßÔöÇ¿¼Á£¬Ó¦ÓÃǰ¾°½ÏºÃ¡£
¾ßÓнϺÃϸ°ûתÔËÐÔÄܵÄPNA-¹¦ÄÜÐÔÅäÌåÁ¬½ÓÎﻹÓÐÒÔϼ¸ÖÖ¡£BendifallahµÈ[52]Ìá³öÁËÒ»ÖÖÁ¬½ÓPNAÓ빦ÄÜÐÔÅäÌåµÄ2-([N-Boc-°±»ùÒÒËá]¼×Ñõ»ù) ±½¼×Ëáõ¥¼ü½á¹¹£¬Í¨¹ý¸Ãõ¥¼ü½á¹¹½«PNAÓë½ð¸ÕÍé¹²¼ÛÁ¬½ÓµÃµ½PNA-õ¥¼ü-½ð¸ÕÍéÁ¬½ÓÎͨ¹ýIMR-90ϸ°ûÖеÄתÔËʵÑéºÍHeLa pLuc705ϸ°ûµÄ·´Òå»îÐÔʵÑ飬·¢ÏÖ¸ÃÁ¬½ÓÎïÄÜ˳Àû½øÈëIMR-90ϸ°û²¢ÔÚϸ°ûºË¸½½ü¾Û¼¯£¬Æä·´Òå»îÐÔÓÐÒ»¶¨µÄÌá¸ß£¬µ«²»Ì«ÏÔÖø¡£¸ÃÁ¬½ÓÎïÁíÒ»ÌØÐÔÊǽṹÖеÄõ¥¼üÔÚÌåÍâÎȶ¨£»¶øÔÚÌåÄÚ£¬ÓÉÓÚøµÄ×÷Óã¬Îȶ¨ÐÔϽµ 2 000-3 000±¶¡£Òò´Ë£¬PNA-õ¥¼ü-½ð¸ÕÍéÁ¬½ÓÎïÔÚÌåÄÚÄÜ·Ö½âΪPNAºÍ½ð¸ÕÍ飬ÕâÖÖõ¥¼ü½á¹¹¾ßÓпª·¢³É¡°Ç°Ò©¡±µÄDZÁ¦¡£DasµÈ[53]·¢ÏÖPNAÓëÐÂÃ¹ËØµÄÁ¬½ÓÎï¾ßÓÐÁ¼ºÃµÄϸ°ûÉãÈëˮƽ£¬¶øÇÒ£¬¼õÉÙ°±»ù»ùÍÅÊýÄ¿£¬µÃµ½µÄPNA-°±»ùÆÏÌÑÌǰ·Á¬½ÓÎïµÄתÔËЧ¹û¸üºÃ¡£ÐÂÃ¹ËØÊÇÒ»ÖÖ°±»ùÌÇÜÕÀ࿹ÉúËØ£¬Í¨¹ýÓë16S rRNA½áºÏ£¬µ¼Ö mRNA±àÂë´íÎ󣬴ӶøÒÖÖÆÏ¸¾úµ°°×Öʺϳɡ£½«6-°±»ùÆÏÌÑÌǰ·»·ÓëHIV-1 TAR RNA»¥²¹µÄÊ®Áù¾ÛPNAÁ¬½Ó£¬ËùµÃµ½µÄÁ¬½ÓÎïÓë°ÐÐòÁнáºÏÀι̣¬¶øÇÒÔÚ±»HIV-1¸ÐȾµÄϸ°ûÖУ¬ÓÐЧµØÒÖÖÆÁ˲¡¶¾¸´ÖÆ£¬¶øÔÚͬÑùÌõ¼þÏ£¬Î´ÐÞÊÎPNAºÜÄѽøÈëϸ°û¡£BrowneµÈ[54]½«PNAÒÔ²»Í¬µÄ·½Ê½ÓëÁ½ÖÖάÉúËØEÁ¬½Ó£¬ÆäÖÐÒ»ÖÖ´øÓг¤Ì¼Á´£¬µÃµ½µÄÁ¬½Ó¸´ºÏÎïÖв¿·Ö¾ßÓнϺõÄÔÓ½»ÌØÐÔ£¬²¢ÇÒÌá¸ßÁËPNAµÄϸ°ûÉãÈëˮƽºÍÉúÎïÀûÓöȡ£¶øÇÒάÉúËØE×ÔÉíÊÇÒ»ÖÖÌØ¸ßÃâÒßÁ¦µÄÒ©Î¾ßÓÐÇå³ýÌåÄÚ×ÔÓÉ»ù¡¢¿¹Ë¥ÀϵŦÄÜ¡£Òò´Ë£¬ÕâÖÖÁ¬½ÓÎï²»µ«²»»áÓÐϸ°û¶¾ÐÔ£¬¶øÇÒ»¹¾ßÓÐPNAÓëάÉúËØEµÄЭͬÖÎÁƵÄDZÔÚÓ¦Óá£
3 ½áÓïÓëÕ¹Íû
PNA×Ô1991ÄêÌá³öÒÔÀ´£¬ÓÉÓÚ¾ßÓÐÓÅÒìµÄÔÓ½»ÐÔÄÜ¡¢Îȶ¨µÄ½á¹¹ÌØÐÔ¼°·½±ãÓÐЧµÄºÏ³É·½·¨Êܵ½ÖØÊÓ£¬Ëæ×Ÿ÷ÖÖе¥ÌåµÄ³É¹¦ºÏ³ÉºÍ¹Ñ¾ÛÌåÐÞÊεÄÑо¿£¬PNAµÄÓ¦ÓÃÁìÓò²»¶ÏÍØÕ¹¡£ÔçÆÚ×÷Ϊ·Ö×ÓÉúÎïѧ¹¤¾ß£¬ÔÚ»ùÒò¼ì²â¡¢Ò½ÁÆÕï¶ÏºÍÉúÎï´«¸ÐÆ÷µÈ·½ÃæÈ¡µÃÁ˽ϺõÄÓ¦Ó᣽üÄêÀ´£¬¶ÔPNAµÄÑо¿µÄÈȵã֮һתÏò»ùÒòÖÎÁÆ£¬Í¨¹ý¶ÔPNAµÄÐÞÊÎÓë¸ÄÔ죬¿ª·¢PNA·´ÒåÒ©ÎïµÄDZÁ¦¡£Ä¿Ç°£¬PNAÔÚ·´ÒåÒ©Îï·½ÃæÓ¦ÓõÄ×î´óÕϰ­ÊÇϸ°ûתÔ˲²¢µ¼ÖÂÉúÎïÀûÓöȵͣ¬³ÉÒ©ÐԲ
ΪÌá¸ßPNAµÄϸ°ûתÔË£¬°üÀ¨Ï¸°ûĤ¸ÄÔì¡¢¹Ç¼ÜÐÞÊΡ¢ÅäÌåÐÞÊεȷ½·¨µÄ³É¹¦Ó¦Óã¬ÔÚ¸ÄÉÆPNAϸ°ûÉãÈëˮƽ²îµÄÄÑÌâÉÏÒÑÈ¡µÃÁËÒ»¶¨½øÕ¹£¬²¿·ÖµØ½â¾öÁËÕâЩÎÊÌâ¡£µ«ÊÇ£¬Ä¿Ç°µÄÑо¿Ö÷Òª´¦ÓÚÌåÍâϸ°ûˮƽ£¬PNAÔÚÉúÎïÌåÄÚµÄÎüÊÕ¡¢´úл¼°Ï¸°ûתÔË·½Ã滹ÓдýÓÚ½øÒ»²½Ì½ÌÖ¡£Æù½ñ»¹Ã»ÓÐPNAÒ©Îï½øÈëÁÙ´²Ñо¿½×¶Î£¬ÕâÓëPNAµÄÉúÎïÀûÓöȺÍϸ°û¶¾ÐԵȷ½ÃæµÄȱÏÝ£¬ÒÔ¼°È±·¦ÌåÄÚÑо¿Êý¾ÝÓйء£
½ñºó£¬¸ÄÉÆPNAµÄϸ°ûתÔËÐÔÄÜÊÇÑо¿µÄÖØµãÖ®Ò»¡£ÎÒÃÇÈÏΪ¶ÔPNA×ÔÉí½á¹¹µÄÐÞÊÎÔÚ³ÉÒ©ÐÔ·½Ãæ±Èϸ°ûÄ¤ÉøÍ¸·¨ºÍµçÖ¿׷¨¸üΪÓÐЧ£¬¿ª·¢ÊʺϵĹǼܽṹºÍѰÕÒÓÐЧµÄÅäÌåÒýµ¼»¯ºÏÎï¿ÉÄÜÊÇ´Ù½øPNAÔÚ·´ÒåÒ©Îï·½ÃæÈ¡µÃÍ»ÆÆµÄÒ»ÏîÖØÒª¹¤×÷¡£Ä¿Ç°£¬Òѱ¨µÀµÄ¹Ç¼ÜÐÞÊÎÐÍPNA´óÔ¼Óм¸Ê®ÖÖ£¬´ÓË®ÈÜÐÔ¡¢ÔÓ½»ÐÔÄÜ¡¢Ï¸°ûתÔËÐÔÄܵÈɸѡָ±ê³ö·¢£¬²¿·Ö¹Ç¼ÜÐÞÊÎPNA¾ßÓнϺõÄÓ¦ÓÃǰ¾°¡£Í¬Ê±£¬PNAµÄÔÓ½»ÐÔÄÜÓë¹Ç¼Ü¿Õ¼ä¹¹ÐÍÃÜÇÐÏà¹Ø£¬¶ÔPNA¹Ç¼Ü½øÐÐÐÞÊÎÓ¦ÔÚ±£³ÖÆä¹Ç¼Ü»ù±¾¹¹ÐͲ»±äµÄ»ù´¡ÉϽøÐС£Õâ¸øPNAµÄ¹Ç¼ÜÐÞÊÎÌá³öÁ˽ÏΪ¿Á¿ÌµÄÒªÇ󣬲¢ÔÚÒ»¶¨³Ì¶ÈÉÏÏÞÖÆÁ˹ǼÜÐÞÊÎÐÍPNAµÄ½á¹¹±ä»¯¡£¶øÍ¨¹ýÑ¡ÔñºÏÊʵÄÅäÌ壬ÓëPNA¹²¼ÛÁ¬½ÓÐγÉPNA-ÅäÌåÁ¬½ÓÎï²»¸Ä±äPNA×ÔÉíÌØÐÔ£¬µ«¸³ÓèPNAÔÚÖîÈçϸ°û¶¾ÐÔ¡¢Ò©Àí»îÐÔÒÔ¼°Ï¸°ûÉãÈ¡Âʵȷ½Ãæ¸üÓÅÒìµÄÐÔÄÜ£¬¾ßÓиüºÃµÄÓ¦ÓÃǰ¾°¡£±¾ÊµÑéÊÒ½«¿¹²¡¶¾Ò©ÎïºÍÔöÇ¿ÃâÒßÁ¦Ò©ÎïÓëPNA¹Ñ¾ÛÌåNÄ©¶Ë¹²¼ÛÁ¬½Ó£¬¶¯ÎïÁÙ´²ÊµÑé½á¹û±íÃ÷£¬PNA-Ò©ÎïÁ¬½ÓÎïÖÎÁÆÐ§¹û¸üºÃ¡£Í¬Ê±£¬ÎÒÃÇÈÏΪ¿ÉÒÔÔÚÒÔϼ¸·½Ãæ×÷³¢ÊÔ£ºµÚÒ»£¬½«PNA¹Ç¼ÜÐÞÊÎÓëÅäÌåÁ¬½ÓÎïÐÞÊνáºÏ£¬Ê×ÏȺϳɾßÓÐÁ¼ºÃתÔËDZÁ¦µÄ¹Ç¼ÜÐÞÊε¥ÌåPNA£¬ÔÚ¾ÛºÏʱ£¬ÔڹѾÛÌåÄ©¶Ë»òÖмäÒýÈëÒýµ¼ÅäÌ壬×ÛºÏÀûÓÃÁ½ÖÖÐÞÊεÄÓŵ㣻µÚ¶þ£¬½«PNAÐÞÊÎÎïÓëÖÆ¼Á¿ª·¢ÊֶνáºÏ£¬Èç²ÉÓÃÖ¬ÖÊÌå¡¢ÄÉÃ×Á£µÈÖÆ¼Áм¼ÊõЭÖúÐÞÊÎÐÍPNAתÔË£¬´Ù½øPNAµÄÁÙ´²Ó¦Ó㻵ÚÈý£¬¿ª·¢¾ßÓÐÔöǿתÔ˵ŦÄÜÐÔ»¯ºÏÎÈçǰËùÊö£¬Î¬ÉúËØE¡¢°¢Ë¾Æ¥ÁÖ¡¢·úÄáÐÁµÈÒ©Îï¼È¿É×÷ΪPNAתÔËÒýµ¼»¯ºÏÎͬʱ×ÔÉíÓÖ¾ßÓÐÌØ¶¨µÄÒ©Àí»îÐÔ£¬ÕâÖÖPNAÁ¬½ÓÎï¾ßÓÐË«ÖØÖÎÁƵÄÓÅÒìÐÔÄÜ¡£
ÃâÔðÉùÃ÷£º±¾ÎÄΪÐÐÒµ½»Á÷ѧϰ£¬°æÈ¨¹éÔ­×÷ÕßËùÓУ¬ÈçÓÐÇÖȨ£¬¿ÉÁªÏµÉ¾³ý
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:

²é¿´È«²¿É¢½ðÌù

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
tzynew2Â¥
2022-12-16 18:20   »Ø¸´  
רע¶àëÄ(½ð±Ò+1): лл²ÎÓë
XG-WUST3Â¥
2022-12-16 19:36   »Ø¸´  
רע¶àëÄ(½ð±Ò+1): лл²ÎÓë
up ·¢×ÔСľ³æIOS¿Í»§¶Ë
nono20094Â¥
2022-12-20 06:26   »Ø¸´  
רע¶àëÄ(½ð±Ò+1): лл²ÎÓë
¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ºÏ·ÊëÄ¿âÉúÎï µÄÖ÷Ìâ¸üÐÂ
Ìáʾ: Èç¹ûÄúÔÚ30·ÖÖÓÄڻظ´¹ýÆäËûÉ¢½ðÌù£¬Ôò¿ÉÄÜÎÞ·¨ÁìÈ¡´ËÌù½ð±Ò
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼²©] 26É격×Ô¼ö +6 Íé»ù°Ëµª- 2026-03-06 7/350 2026-03-06 23:50 by wszdzda
[¿¼ÑÐ] Çóµ÷¼Á +4 ºôºô£¿~+123456 2026-03-05 5/250 2026-03-06 23:15 by L135790
[¿¼ÑÐ] Ò»Ö¾Ô¸¹þ¶û±õ¹¤Òµ´óѧ0856²ÄÁÏÓ뻯¹¤£¬Ç°Èý¿Æ206£¬×Ü·Ö283£¬Çóµ÷¼Á +6 26¿¼ÑÐÇóµ÷¼Á 2026-03-06 6/300 2026-03-06 18:03 by caszguilin
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤328Çóµ÷¼Á +4 ¡££¬¡££¬¡££¬¡£i 2026-03-02 4/200 2026-03-06 16:24 by @ìªìªìªìª
[¿¼ÑÐ] 290·Ö²ÄÁϹ¤³Ì085601Çóµ÷¼Á Êý¶þÓ¢Ò» +9 llx0610 2026-03-02 10/500 2026-03-06 16:24 by @ìªìªìªìª
[¿¼ÑÐ] ²ÄÁÏѧ˶318Çóµ÷¼Á +21 February_Feb 2026-03-01 24/1200 2026-03-06 16:08 by @ìªìªìªìª
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤£¨¸ß·Ö×Ó£©290·ÖÇóµ÷¼Á +9 wengyujian 2026-03-04 9/450 2026-03-06 15:59 by ´ÏÃ÷µÄ´óËÉÊó
[¿¼ÑÐ] 268Çóµ÷¼Á +4 ÁõºÏ»ª 2026-03-05 4/200 2026-03-06 11:18 by lature00
[¿¼ÑÐ] 287Çóµ÷¼Á +3 ¿´¿´ÎÒ. 2026-03-05 6/300 2026-03-06 10:40 by Iveryant
[¿¼ÑÐ] ²ÄÁÏ¿¼ÑÐ339Çóµ÷¼Á +3 Karry*^_^* 2026-03-04 3/150 2026-03-06 00:32 by wutongshun
[¿¼ÑÐ] Ò»Ö¾Ô¸ËÕ´ó²ÄÁϹ¤³Ìר˶293Çóµ÷¼Á +3 ¸ÖÌú´óÅÚ 2026-03-04 3/150 2026-03-05 21:07 by ºÚÒÂÂøÍ·ÈË
[¿¼ÑÐ] ½­Î÷ʦ·¶´óѧÍõÀ¥-¬Õ»ԿÎÌâ×éÕл¯Ñ§·½Ïò˶ʿÑо¿ÉúÁ½Ãû +3 ¹þ¹þ´óÏÀ 2026-02-28 3/150 2026-03-05 14:01 by happy-john
[¿¼ÑÐ] Ò»Ö¾Ô¸Ç廪ÉîÑÐÔº²ÄÁÏר˶294·Ö£¬×¨Òµ¿Î111·Ö£¬±¾¿ÆÖÐÄÏ´óѧ²ÄÁÏ£¬ÓÐÁù¼¶£¬Óй¤×÷¾­Ñé +3 H14528 2026-03-04 3/150 2026-03-05 10:35 by ms629
[¿¼ÑÐ] 0703»¯Ñ§ ѧ˶ Àí¹¤¿Æ¾ù¿É ²»Çø·ÖÑо¿·½Ïò ×Ü·Ö279Çóµ÷¼Á +7 1Ò»11 2026-03-03 7/350 2026-03-05 09:23 by xwxstudy
[¿¼ÑÐ] 322·Ö 085600Çóµ÷¼Á£¬Óл¥ÁªÍø+¹ú½ð¼°Ö÷³ÖÊ¡¼¶´ó´´¾­Àú +6 Ðܾ³†´ 2026-03-04 6/300 2026-03-04 20:32 by kakakapanpan
[¿¼ÑÐ] Ò»Ö¾Ô¸Öпƴó080500×Ü·Ö324Çóµ÷¼Á +3 jorna 2026-03-03 6/300 2026-03-04 16:20 by »¨¿ª¸»¹óÐÒ¸£ÈËÉ
[¿¼ÑÐ] ²ÄÁÏ270Çóµ÷¼Á 6+6 Eiiiio 2026-03-01 11/550 2026-03-03 15:04 by Phoebelala
[¿¼ÑÐ] »¯¹¤×¨Ë¶348£¬Ò»Ö¾Ô¸985Çóµ÷¼Á +8 ¸¥¸ñ¸ö 2026-02-28 11/550 2026-03-03 14:55 by relum
[¿¼ÑÐ] »¯¹¤¾©Çø271Çóµ÷¼Á +7 11ing 2026-03-02 7/350 2026-03-03 07:30 by ÀûºÃÀûºÃ.
[¿¼ÑÐ] 1 +5 2026¼ÆËã»ú_³ÏÐÄ 2026-03-01 8/400 2026-03-02 11:05 by Íô£¡£¿£¡
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û